VM

Vincent Miles

Executive Director at Abingworth

Boston, Massachusetts

Invests in

Stages:

  • Min Investment:

    $15,000,000.00
  • Max Investment:

    $30,000,000.00
  • Target Investment:

    $22,500,000.00

Work Experience

  • Executive Director

    2022

  • Partner

    2007 - 2022

    Representing Abingworth, have served on the Boards of Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Hydra Biosciences, IFM Therapeutics, IFM Due, IFM Tre, IFM Quattro, Magellan Diagnostics, Personalis and PrimeraDx, and as a Board observer at Atsena Therapeutics and Nido Biosciences. Abingworth is a life-sciences venture capital firm that invests mainly in companies discovering and developing novel therapeutics for unmet clinical needs.

  • Senior VP, Business Development

    2003 - 2007

  • VP, Business Development, Technology Management

    1997 - 2003

  • Director, Office of Technology Transfer

    1996 - 1997

  • VP, R&D and Business Development

    1992 - 1996

1986 - 1992

  • VP, International Marketing (Molecular Biology Division)

    1989 - 1992

  • VP, R&D (Molecular Biology Division)

    1986 - 1990

  • R&D and Business Development

    1978 - 1986

  • Higher Scientific Officer

    1975 - 1978